Search

Introduction:Cervical carcinoma is the second most common malignancy in women worldwide. It is estimated that over a million women worldwide currently have cervical cancer. Worldwide, cervical cancer is both the fourth-most common cancer and the fourth-most common cause of death from cancer in women. In 2012, 528, 000 new cases of cervical cancer were diagnosed, and 266, 000 women died of the disease (GLOBOCAN 2012), nearly 90% of them in lowto middle-income class countries. Multifactorial causation, potential for prevention, and the sheer threat it poses make cervical cancer an important disease for in-depth studies, as has been attempted by this paper by studying the hypoxic marker. Recently, there has been increasing interest in the identification of biomarkers able to predict both response to treatment and survival. Aim: The aim of this study was to evaluate the association of hypoxic marker Carbonic anhydrase (CAIX) markers to predict the clinical outcome of patients with cervical carcinoma. Materials and methods:This study was conducted on biopsy proven previously untreated cases of cancer cervix who presented to the Department of Radiotherapy at King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India. The study was a single institution, non-randomised, prospective study to evaluate carbonic anhydrase IX as a biomarker in cancer cervix patients undergoing radiotherapy. Sample size: Total 75 samples • 25 healthy control subjects (Age and sex matched) • 25 cancer cervix patients (duplicate samples i.e. baseline and follow up). Approximately 2 ml of blood was withdrawn before initiation of treatment and at the time of first follow up. Standard treatment was given as external beam radiotherapy (EBRT) with concurrent chemotherapy followed by intracavitary radiotherapy (ICRT). Blood samples was analysed for the level of CAIX..Statistical analyses was performed with the SPSS software package v13.0. Results: Pre-treatment high level of carbonic anhydrase IX correlated with poor treatment outcome. [ABSTRACT FROM AUTHOR]